Dare Bioscience announces Notice of Award of grant from NIAID

Dare Bioscience (DARE) announced that it received a Notice of Award of a grant from the National Institute of Allergy and Infectious Diseases, NIAID, a component of the National Institutes of Health, NIH. The award will support non-clinical activities to support the development of DARE-HPV. “DARE-HPV has the potential to be the first FDA-approved pharmaceutical intervention that could treat both late-stage cervical lesions as well as earlier stage HPV-related cervical infections, which could change the paradigm around how HPV-related cervical diseases are clinically managed today,” said Sabrina Martucci Johnson, President and CEO of Dare Bioscience. “We are striving to transform the management of HPV-related cervical diseases with this at-home strategy to control the virus that causes cervical cancer.”